| 1. |
- Boito, Deneb, 1993-, et al.
(författare)
-
Diffusivity-limited q-space trajectory imaging
- 2023
-
Ingår i: Magnetic Resonance Letters. - : KeAi Publishing Communications. - 2772-5162. ; 3:2, s. 187-196
-
Tidskriftsartikel (refereegranskat)abstract
- Q-space trajectory imaging (QTI) allows non-invasive estimation of microstructural features of heterogeneous porous media via diffusion magnetic resonance imaging performed with generalised gradient waveforms. A recently proposed constrained estimation framework, called QTI+, improved QTI’s resilience to noise and data sparsity, thus increasing the reliability of the method by enforcing relevant positivity constraints. In this work we consider expanding the set of constraints to be applied during the fitting of the QTI model. We show that the additional conditions, which introduce an upper bound on the diffusivity values, further improve the retrieved parameters on a publicly available human brain dataset as well as on data acquired from healthy volunteers using a scanner-ready protocol.
|
|
| 2. |
- Gullestad, L., et al.
(författare)
-
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
- 2012
-
Ingår i: European Heart Journal. - : Oxford University Press (OUP). - 0195-668X .- 1522-9645. ; 33:18, s. 2290-2296
-
Tidskriftsartikel (refereegranskat)abstract
- To investigate whether plasma galectin-3, a mediator of fibrogenesis, can identify patients with chronic heart failure (HF) for whom statins are effective. Patients with ischaemic systolic HF enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) were randomly assigned to 10 mg/day of rosuvastatin or placebo. Galectin-3 was measured in plasma. The primary outcome was cardiovascular death, myocardial infarction, or stroke. Of 1492 patients, 411 had a primary event during a median follow-up of 32.8 months. There was an interaction between baseline galectin-3 and rosuvastatin on the primary endpoint (P-value for interaction 0.036). Among patients with below the median plasma concentrations of galectin-3 (19.0 ng/mL), those assigned to rosuvastatin had a lower primary event rate [hazard ratio (HR) 0.65; 95 confidence interval (CI), 0.460.92; P 0.014], lower total mortality (HR 0.70; 95 CI, 0.500.98; P 0.038), and lower event rate of all-cause mortality and HF hospitalizations (HR 0.72; 95 CI, 0.540.98; P 0.017) compared with placebo, but no benefit was observed in patients with higher levels of galectin-3. The combination of concurrently low concentrations of galectin-3 and N-terminal pro-B-type natriuretic peptide (102.7 pmol/L) identified patients with a large benefit with rosuvastatin (HR 0.33; 95 CI, 0.160.67; P 0.002). Patients with systolic HF of ischaemic aetiology who have galectin-3 values 19.0 ng/mL may benefit from rosuvastatin treatment. However, the data from this post hoc analysis should be interpreted with caution since the overall results of the CORONA study did not show a significant effect on the primary endpoint.
|
|
| 3. |
- Gulliksen, J, et al.
(författare)
-
Accessibility through Standardisation
- 2001
-
Ingår i: In Proceedings of the 1st international conference on Universal Access of Human-Computer Interfaces, UAHCI 2001, New Orleans.
-
Konferensbidrag (refereegranskat)
|
|
| 4. |
- Gulliksen, Jan, 1965-, et al.
(författare)
-
Accomplishing universal access through system reachability : a management perspective
- 2004
-
Ingår i: Universal Access in the Information Society. - : Springer Berlin/Heidelberg. - 1615-5289 .- 1615-5297. ; 3:1, s. 96-101
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of this paper is to describe the need of a method by which we can estimate the return on accessibility investments in information technology (IT) systems. This paper reveals some of the reasons why accessibility still is a secondhand criterion when designing digital services. It also describes the authors experiences regarding the concept of accessibility and how it must develop in order to obtain the status of a basic business criterion for the benefit of disabled people who are currently excluded from public services and labour markets. The paper also questions the need of a separate accessibility standard. Additionally, we discuss some of the hindering in the market and limiting perspectives that are blocking further development. One of the problems in the market seems to be that accessibility as a concept has been more of an issue about creating equal opportunities and therefore probably does not have the quality of a business criterion. In order to bridge that gap, we argue for replacing accessibility with reachability, which is a concept based on a measure used by media when estimating the reached percentage of a population or target group.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Gulliksen, J., et al.
(författare)
-
KAN EN STANDARD VARA TILL NÅGON HJÄLP I DESIGNARBETE?
- 1999
-
Ingår i: Designjournalen. - : Stockholm: Svensk Industridesign. - 1400-8963. ; 6:1
-
Tidskriftsartikel (refereegranskat)abstract
- Att en standard kan fylla en funktion när en skruv tillverkad av ett företag i ett land skall passa ihop med en mutter tillverkad av ett annat företag i ett helt annat land kan väl av de allra flesta ses som en självklarhet. Men vad är då egentligen en
|
|
| 8. |
|
|
